CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Technetium Tc-99m Sulfur Colloid +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00832429
NCT00832429Phase 2Completed
CompareCT.gov

Sentinel Lymph Node Localization and Biopsy for Sebaceous Gland Carcinoma of the Eyelid

M.D. Anderson Cancer Center·interventional·Posted Jan 30, 2009·Updated Jul 4, 2025

In Brief

A Phase 2 clinical trial evaluating Lymph Node Mapping, Sentinel Lymph Node Biopsy, and 1 other intervention for Eyelid Sebaceous Gland Carcinoma. Completed, enrolled 20 participants across 1 site.

Detailed Summary

This phase II trial studies how well lymph node mapping works in finding disease that has spread from the place where it started to other places in the body in patients with sebaceous gland cancer of the eyelid. Lymph node mapping may help in planning surgery to remove cancer and affected lymph nodes.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEyelid Sebaceous Gland Carcinoma
CountriesUnited States
CollaboratorsNational Cancer Institute (NCI)

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 30, 2009
Enrollment StartFeb 25, 2009
Primary CompletionAug 27, 2024
TodayJul 2, 2026
Enrollment to primary: 15.5 yearsPosted 17.4 years ago

Interventions

Lymph Node Mappingprocedure

Undergo lymph node mapping

Sentinel Lymph Node Biopsyprocedure

Undergo SLN biopsy

Technetium Tc-99m Sulfur Colloiddrug

Given ID